Phase II, Multicenter, Randomized, Open-Label Study of a Sequential Treatment of Intermittent Erlotinib and Docetaxel Versus Erlotinib Alone in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer After Failure of a Prior Chemotherapy Regimen.

Trial Profile

Phase II, Multicenter, Randomized, Open-Label Study of a Sequential Treatment of Intermittent Erlotinib and Docetaxel Versus Erlotinib Alone in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer After Failure of a Prior Chemotherapy Regimen.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Preliminary results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Sep 2011 Preliminary results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 07 Jul 2011 Interim results presented at the 14th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top